Literature DB >> 28462715

Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension.

Michalis Doumas1, Chrysoula Boutari1, Costas Tsioufis2, Kyriakos Dimitriadis2, Areti Triantafyllou3, Stella Douma3.   

Abstract

INTRODUCTION: Resistant hypertension (HT) is a common clinical entity with debilitating cardiovascular consequences. The highly heterogeneous nature of resistant HT requires a meticulous workup to exclude 'pseudo-resistance' and secondary forms of arterial HT. Resistant HT has recently gained wide scientific interest due to the introduction of interventional methods (renal sympathetic denervation and carotid baroreceptor stimulation) for blood pressure (BP) reduction in this patient population. Despite however the recent advances in understanding the pathophysiology and the clinical characteristics of the disease, the appropriate management of resistant HT remains elusive. The marked heterogeneity of BP response to interventional therapy underlines the need for careful patient selection and the identification of ideal candidates for interventional therapy.
CONCLUSION: The renin-angiotensin-aldosterone system seems to play a cardinal role in the pathophysiology of resistant HT and requires appropriate management. Furthermore, primary aldosteronism is considered the most common form of secondary HT, with increased prevalence in patients with resistant HT. This review aims to provide a simplified work-up for patients with resistant HT, summarize the rationale for the determination of renin and aldosterone levels, and critically discuss available evidence on when and how to measure renin/aldosterone in resistant HT. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Resistant hypertension; aldosterone; primary aldosteronism; renal sympathetic denervation; renin

Mesh:

Substances:

Year:  2017        PMID: 28462715     DOI: 10.2174/1570161115666170426145612

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  3 in total

1.  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-12-13       Impact factor: 3.738

2.  Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Michael Doumas
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-07-18       Impact factor: 3.738

Review 3.  The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism.

Authors:  Gian Paolo Rossi; Valeria Bisogni; Alessandra Violet Bacca; Anna Belfiore; Maurizio Cesari; Antonio Concistrè; Rita Del Pinto; Bruno Fabris; Francesco Fallo; Cristiano Fava; Claudio Ferri; Gilberta Giacchetti; Guido Grassi; Claudio Letizia; Mauro Maccario; Francesca Mallamaci; Giuseppe Maiolino; Dario Manfellotto; Pietro Minuz; Silvia Monticone; Alberto Morganti; Maria Lorenza Muiesan; Paolo Mulatero; Aurelio Negro; Gianfranco Parati; Martino F Pengo; Luigi Petramala; Francesca Pizzolo; Damiano Rizzoni; Giacomo Rossitto; Franco Veglio; Teresa Maria Seccia
Journal:  Int J Cardiol Hypertens       Date:  2020-04-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.